Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.42 |
| ▸ | PPARD | Q03181 | 8/20 | 0.41 |
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070582 | 0.79 | PPARD (0.60) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL3071111 | 0.79 | TARBP2 (0.70) | TARBP2PPARDPPARAMAPTKDM4E | |
| SCHEMBL5657427 | 0.77 | NPC1 (0.55) | FFAR1PPARDPPARAPPARGMAPT | |
| SCHEMBL13139700 | 0.76 | TRPM8 (0.53) | TARBP2FFAR1PPARDPPARAPPARG | |
| SCHEMBL3082591 | 0.76 | PPARD (0.45) | TARBP2FFAR1PPARDPPARAPPARG | |
| SCHEMBL3069938 | 0.74 | TARBP2 (0.54) | TARBP2PPARDPPARAMAPTKDM4E | |
| SCHEMBL3086530 | 0.70 | HPGD (0.46) | FFAR1PPARDPPARAPPARGMAPT | |
| SCHEMBL3074369 | 0.68 | HRH3 (0.71) | TARBP2PPARDPPARAALDH1A1SMN1; SMN2 | |
| SCHEMBL8867253 | 0.68 | TARBP2 (0.67) | TARBP2FFAR1PPARDPPARAPPARG | |
| SCHEMBL3076700 | 0.67 | HRH3 (0.55) | TARBP2PPARDPPARAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790720-B2 | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses | UCB PHARMA, S.A. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | OXER1, OXTR, OGFR | TARBP2 4543/4885FFAR1 209/4885PPARD 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.